Compare Stocks

→ Automatic Income (from home) (From Awesomely, LLC) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$5.35 -1.8%	$6.28	$2.78 ▼ $8.85	$29.05M	1.08	6,323 shs	2,249 shs
CBIO Catalyst Biosciences		$0.77	$0.19 ▼ $8.69	$291.29M	1.05	763,526 shs	32,246 shs
OTIC Otonomy	$0.01	$0.06	$0.01 ▼ $2.54	$582K	1.54	937,525 shs	N/A
PLXP PLx Pharma		$0.00	$0.02 ▼ $0.04	$603K	3.79	12.96 million shs	3,000 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	-1.83%	+2.88%	-15.21%	-6.47%	+38.96%
CBIO Catalyst Biosciences	0.00%	0.00%	0.00%	0.00%	+3,533.11%
OTIC Otonomy	0.00%	0.00%	0.00%	0.00%	0.00%
PLXP PLx Pharma	0.00%	0.00%	0.00%	0.00%	-97.78%

The Gold Grab of the Century (Ad)

When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APRE Aprea Therapeutics	3.5333 of 5 stars	3.5	5.0	0.0	0.0	2.6	3.3	0.6
CBIO Catalyst Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OTIC Otonomy	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	3.00	Buy	$15.50	189.72% Upside
CBIO Catalyst Biosciences	N/A	N/A	N/A	N/A
OTIC Otonomy	N/A	N/A	N/A	N/A
PLXP PLx Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest PLXP, APRE, CBIO, and OTIC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/27/2024	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$9.00 ➝ $11.00
3/26/2024	APRE Aprea Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00

(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$580K	50.09	N/A	N/A	$4.54 per share	1.18
CBIO Catalyst Biosciences	$790K	0.00	N/A	N/A	($0.78) per share	0.00
OTIC Otonomy	$130K	4.48	N/A	N/A	$0.97 per share	0.01
PLXP PLx Pharma	$4.54M	0.00	N/A	N/A	$1.30 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$14.29M	-$3.99	N/A	N/A	N/A	N/A	-65.58%	-52.37%	5/20/2024 (Estimated)
CBIO Catalyst Biosciences	-$8.24M	-$1.38	N/A	N/A	N/A	N/A	-364.68%	-281.68%	N/A
OTIC Otonomy	-$51.18M	-$0.77	N/A	∞	N/A	N/A	-137.86%	-68.50%	N/A
PLXP PLx Pharma	-$46.13M	-$1.85	N/A	N/A	N/A	-606.91%	-291.11%	-119.43%	N/A

Latest PLXP, APRE, CBIO, and OTIC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/26/2024	Q4 2023	APRE Aprea Therapeutics	-$0.56	-$0.92	-$0.36	-$0.92	$0.33 million	$0.01 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
CBIO Catalyst Biosciences	N/A	N/A	N/A	N/A	N/A
OTIC Otonomy	N/A	N/A	N/A	N/A	N/A
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	5.13	5.13
CBIO Catalyst Biosciences	N/A	2.88	2.88
OTIC Otonomy	N/A	1.74	1.74
PLXP PLx Pharma	N/A	4.79	4.28

Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
CBIO Catalyst Biosciences	5.98%
OTIC Otonomy	41.23%
PLXP PLx Pharma	21.19%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	20.90%
CBIO Catalyst Biosciences	2.92%
OTIC Otonomy	1.09%
PLXP PLx Pharma	8.95%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	5.43 million	4.30 million	No Data
CBIO Catalyst Biosciences	7	37.98 million	36.87 million	Optionable
OTIC Otonomy	51	68.53 million	67.78 million	Optionable
PLXP PLx Pharma	16	29.14 million	26.53 million	Not Optionable

PLXP, APRE, CBIO, and OTIC Headlines

Source	Headline
	Protalix Biotherapeutics Inc (PLX) investing.com - January 30 at 9:00 AM
	Vertex Pharmaceuticals Inc VRTX morningstar.com - January 22 at 7:59 PM
	Vietnam National Petroleum Group (PLX) investing.com - October 23 at 10:13 AM
	PLx Pharma Inc (PLXPQ) uk.investing.com - August 21 at 4:54 AM
	Pharmaceutical R&D: the road to positive returns nature.com - July 16 at 9:22 AM
	PLXPQ PLx Pharma Inc. seekingalpha.com - April 21 at 11:49 PM
	PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE(R) and Substantially All of its Assets marketwatch.com - April 13 at 10:45 PM
	Why PLx Pharma Shares Are Nosediving Today msn.com - April 12 at 4:03 PM
	Why iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket msn.com - April 12 at 10:33 AM
	Why PLx Pharma Shares Are Down Over 40% Tuesday msn.com - April 11 at 11:47 PM
	PLx Pharma Inc. Receives Nasdaq Delisting Notice finance.yahoo.com - April 11 at 6:43 PM
	Short Volatility Alert: Plx Pharma Inc msn.com - April 11 at 1:42 PM
	PLx Pharma's Return On Capital Employed Insights msn.com - December 22 at 2:37 PM
	PLx Pharma (PLXP) Q3 2022 Earnings Call Transcript seekingalpha.com - November 11 at 11:44 AM
	PLx Pharma down after Q3 revenue fell 94% Y/Y seekingalpha.com - November 11 at 11:44 AM
	PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update finance.yahoo.com - November 10 at 8:33 PM
	PLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue Estimates finance.yahoo.com - November 10 at 8:33 PM
	Earnings Preview: PLx Pharma msn.com - November 10 at 3:32 PM
	PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update finance.yahoo.com - October 26 at 12:57 PM
	Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels finance.yahoo.com - September 12 at 9:15 PM
	PLx Pharma Inc. (NASDAQ:PLXP) drops to US$21m and insiders who purchased earlier this year lose another US$52k finance.yahoo.com - September 5 at 11:30 AM
	PLXP Aug 2022 5.000 call finance.yahoo.com - August 20 at 9:18 PM
	PLx Pharma downgraded at Oppenheimer after Q2 miss seekingalpha.com - August 15 at 2:42 PM
	PLx Pharma to Explore Strategic Alternatives, Reduces Team marketwatch.com - August 12 at 11:28 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aprea Therapeutics

NASDAQ:APRE

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Catalyst Biosciences

NASDAQ:CBIO

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

Otonomy

NASDAQ:OTIC

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

PLx Pharma

NASDAQ:PLXP

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial